Scholars Central

Conference abstractPublished 25 Sep 2014

How to improve quality and consistency of legacy products applying QbD/Six Sigma methodology

Authors: Alicia Tebar

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

ICH Guidelines Q8 to Q11 are the foundations of Quality by Design (QbD). They have been agreed globally and represent an evolution of pharmaceutical quality systems from a model based primarily on inspection, to a risk-based model supported on scientific knowledge and process control. The expected benefit of QbD application has been largely described. Acquiring a thorough knowledge of the process and identify sources of variability, leads to predictable and robust processes. This in turn leads to a quality improvement that ultimately results in lower costs of remediation and inspection. From the regulatory front, the continued process verification requires stable and capable processes, so the ?state of control? has to be demonstrated. From this point of view, mature products with recurring quality problems due to poor development and a lack of process knowledge may be good candidates for a QbD redesign. This is what has come to be called reverse QbD or process reengineering. The presentation presents an application example on a tablet with quality problems, to which QbD methodology is applied in order to identify sources of variability and to propose a new control strategy to achieve consistent quality. In this case the calculation of ROI is used to justify the investment needed for the project.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Developing Drugs.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Alicia Tebar”